tradingkey.logo

Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction In ORIGIN Phase 3 Trial In Adults With IgA Nephropathy

ReutersJun 2, 2025 12:25 PM

- Vera Therapeutics Inc VERA.O:

  • VERA THERAPEUTICS ANNOUNCES ATACICEPT ACHIEVED 46% PROTEINURIA REDUCTION IN ORIGIN PHASE 3 TRIAL IN ADULTS WITH IGA NEPHROPATHY

  • VERA THERAPEUTICS INC - TO SUBMIT BLA FOR ATACICEPT TO FDA IN 4Q 2025

  • VERA THERAPEUTICS INC - ATACICEPT SAFETY PROFILE FAVORABLE AND COMPARABLE TO PLACEBO

  • VERA THERAPEUTICS INC: PRIMARY ENDPOINT WAS MET IN ORIGIN PHASE 3 TRIAL OF ATACICEPT

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI